Akorn, Inc. and CSL Biotherapies Sign a Specialty Distributor Agreement for Afluria(R) (Flu Vaccine)

BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) a specialty pharmaceutical company, and CSL Biotherapies, Inc., a subsidiary of CSL Limited, have entered into a Specialty Distributor Agreement for Afluria®, a seasonal influenza vaccine. Akorn will market and distribute two presentations of Afluria®: pre-filled syringes without latex or thimerosal, and preserved multi-dose vials. Akorn will immediately begin pre-booking sales for the 2008 flu season. According to recent IMS sales data, the current flu vaccine market size in the U.S. and Puerto Rico is approximately $800 million.

Back to news